Czech National Bank Increases Holdings in Boston Scientific Corporation $BSX

Czech National Bank increased its position in shares of Boston Scientific Corporation (NYSE:BSX) by 4.7% in the second quarter, HoldingsChannel reports. The firm owned 423,074 shares of the medical equipment provider’s stock after acquiring an additional 19,180 shares during the quarter. Czech National Bank’s holdings in Boston Scientific were worth $18,057,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also recently bought and sold shares of the company. Vanguard Group Inc. raised its position in Boston Scientific by 1.0% during the 4th quarter. Vanguard Group Inc. now owns 139,685,997 shares of the medical equipment provider’s stock worth $13,319,060,000 after buying an additional 1,436,550 shares during the last quarter. State Street Corp boosted its holdings in shares of Boston Scientific by 1.4% in the 4th quarter. State Street Corp now owns 65,846,059 shares of the medical equipment provider’s stock valued at $6,278,422,000 after acquiring an additional 920,495 shares during the last quarter. Capital World Investors increased its stake in shares of Boston Scientific by 1.9% in the fourth quarter. Capital World Investors now owns 27,151,575 shares of the medical equipment provider’s stock worth $2,588,953,000 after acquiring an additional 502,627 shares during the period. Norges Bank acquired a new stake in shares of Boston Scientific in the fourth quarter worth $2,199,395,000. Finally, Morgan Stanley raised its holdings in shares of Boston Scientific by 10.8% during the fourth quarter. Morgan Stanley now owns 22,960,556 shares of the medical equipment provider’s stock worth $2,189,289,000 after purchasing an additional 2,246,308 shares during the last quarter. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on BSX shares. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and issued a $60.00 price target on shares of Boston Scientific in a report on Thursday, July 30th. Jefferies Financial Group reduced their price objective on Boston Scientific from $100.00 to $67.00 and set a “buy” rating for the company in a research note on Wednesday, June 24th. Mizuho decreased their price objective on Boston Scientific from $90.00 to $70.00 and set an “outperform” rating for the company in a report on Wednesday, July 15th. Barclays lowered their target price on Boston Scientific from $96.00 to $89.00 and set an “overweight” rating on the stock in a research note on Thursday, May 28th. Finally, Robert W. Baird set a $56.00 target price on shares of Boston Scientific in a report on Thursday, July 30th. Twenty-four analysts have rated the stock with a Buy rating, five have given a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, Boston Scientific has a consensus rating of “Moderate Buy” and an average target price of $71.62.

Boston Scientific Stock Up 0.1%

BSX stock opened at $49.35 on Friday. Boston Scientific Corporation has a one year low of $42.20 and a one year high of $109.50. The firm has a market cap of $71.53 billion, a PE ratio of 19.98, a PEG ratio of 1.08 and a beta of 0.56. The firm’s 50 day moving average price is $45.75 and its 200-day moving average price is $60.73. The company has a debt-to-equity ratio of 0.43, a quick ratio of 1.22 and a current ratio of 1.24.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings data on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share for the quarter, topping the consensus estimate of $0.83 by $0.03. Boston Scientific had a return on equity of 19.28% and a net margin of 17.50%.The company had revenue of $5.44 billion during the quarter, compared to analyst estimates of $5.38 billion. During the same period in the prior year, the business posted $0.75 earnings per share. The firm’s revenue for the quarter was up 7.5% compared to the same quarter last year. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. On average, equities research analysts anticipate that Boston Scientific Corporation will post 3.3 EPS for the current year.

Boston Scientific announced that its board has authorized a stock buyback plan on Monday, May 18th that authorizes the company to repurchase $5.00 billion in shares. This repurchase authorization authorizes the medical equipment provider to buy up to 6.4% of its stock through open market purchases. Stock repurchase plans are often a sign that the company’s board believes its shares are undervalued.

Insiders Place Their Bets

In related news, CEO Michael F. Mahoney bought 186,240 shares of the stock in a transaction on Monday, August 3rd. The stock was bought at an average price of $48.33 per share, with a total value of $9,000,979.20. Following the completion of the purchase, the chief executive officer directly owned 1,590,024 shares in the company, valued at $76,845,859.92. This represents a 13.27% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Edward J. Ludwig bought 5,000 shares of the stock in a transaction on Friday, July 31st. The shares were bought at an average cost of $45.48 per share, with a total value of $227,400.00. Following the purchase, the director owned 30,359 shares of the company’s stock, valued at $1,380,727.32. This trade represents a 19.72% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders bought a total of 204,322 shares of company stock valued at $9,939,221 over the last 90 days. Company insiders own 0.34% of the company’s stock.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.